Pfizer
Search results
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases.
Learn more about Bristol Myers Squibb and our mission to discover, develop and deliver innovative medicines to patients with serious diseases.
We promote health equity and seek to improve the health outcomes of populations disproportionately affected by serious diseases. Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.
Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.
Bristol Myers Squibb to Participate in Upcoming Investor Conferences. 05/06/2024. European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... 05/06/2024.
Discover what it means to have a meaningful career. At Bristol Myers Squibb, you'll transform patients' lives and help them prevail over serious diseases.
Jun 24, 2022 · Learn more about the science behind cell therapy and ongoing research at Bristol Myers Squibb here. About Bristol Myers Squibb. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol ...
Learn about global biopharmaceutical innovator Bristol Myers Squibb, helping millions to fight cancer, cardiovascular disease, HIV/AIDS, and more.
Feb 4, 2022 · Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%, driven by Eliquis, our Immuno-Oncology and new product portfolios. U.S. revenues increased 11% to $7.5 billion in the quarter.
